Genetics News

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced the completion of the acquisition of Bako Diagnostics, a premier pathology laboratory, and StrataDx, a premier dermatopathology laboratory, as previously announced on December 22, 2025. Under the terms of the agreement, Fulgent acquired certain assets of Bako Diagnostics and a...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the promotion of Richard Chen, M.D., M.S., to the position of President. Dr. Chen will continue to serve as CMO of Personalis in addition to his new role. The appointment comes at a critical inflection point as Personalis transitions from a pioneering R&D powerhouse into a market leader in Minimal Residual Disease (MRD) testing. Under Dr. Chen’s scientific...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Xaira Therapeutics, a company built to transform drug discovery through AI, today announced X-Cell, its first virtual cell model. Trained on causal, interventional data at unprecedented scale, X-Cell achieves state-of-the-art performance in accurately predicting the outcomes of genetic perturbations — including experiments the model has never seen. This marks a meaningful step toward transforming drug discovery from a trial-and-error process into a...

PHILADELPHIA--(BUSINESS WIRE)--Aro Reports Positive Phase 1b Topline Results for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe Disease (LOPD)...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cellino Appoints Ed Tekeian as Chief Operating Officer...

OXFORD, England & TOKYO--(BUSINESS WIRE)--Oxford Nanopore Technologies, the company delivering a new generation of molecular sensing technology based on nanopores, and A.D.A.M. Innovations (Japanese corporate name Genesis Healthcare Co.), one of Japan’s leading genetic testing companies, today announce an international collaboration to develop and deploy advanced genomic sequencing and medicine applications based on comprehensive, nanopore sequencing in Japan. In its initial phase, the collabor...

BOSTON--(BUSINESS WIRE)--Alloy Therapeutics, Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced an agreement with AbbVie to develop a new antibody platform to discover potent, specific, and effective antibodies against targets that are difficult to address with current technologies. As part of the multi-year agreement, Alloy will receive an upfront payment, as well as an additional payment in connectio...

CAMBRIDGE, England--(BUSINESS WIRE)--Alchemab Therapeutics has appointed Ulrich Wendt as Chief Business Officer to expand partnerships with biopharma for novel antibody therapeutics....

FAIRFAX, Va.--(BUSINESS WIRE)--Fairfax Cryobank and IVI RMA North America, one of the country’s leading providers of reproductive medicine services, today announced a partnership to expand access to diverse, high-quality donor sperm for individuals and couples building their families, along with savings, and access to premium service. Through this partnership, IVI RMA North America patients gain access to a broad network of diverse donors nationwide and a range of programs designed to provide a...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced screening and enrollment are underway in Cohort 8 of ENDEAVOR (Study 9001-103). The purpose of Cohort 8 is to assess prophylactic sirolimus treatment as part of an enhanced safety protocol during treatment with ELEVIDYS (delandistrogene moxeparvovec-rokl) in non-ambulant individuals with Duchenne muscular dystrophy. Data from Cohort 8 will be u...